BusinessCrownBio Launches New Humanized Target Model for ImmunotherapyBy Nasdaq OMXApr 26, 2018, 12:00 PM UTC
BusinessCrownBio to Showcase Scientific Expertise in Preclinical Drug Development at the American Association for Cancer Research (AACR) ConferenceBy Nasdaq OMXApr 4, 2018, 12:00 PM UTC
BusinessCrown Bioscience to Showcase Scientific Expertise at Cambridge UK Symposium: Preclinical Evaluation of Novel ImmunotherapiesBy Nasdaq OMXMar 9, 2018, 1:02 PM UTC
BusinessInnovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live WebinarBy Nasdaq OMXJan 17, 2018, 1:01 PM UTC
BusinessCrown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer PharmacologyBy Nasdaq OMXDec 7, 2017, 3:36 PM UTC
BusinessCrownBio’s Translatable FATZO Model Utilized in Eli Lilly’s Preclinical Type 2 Diabetes Research ProgramsBy Nasdaq OMXNov 21, 2017, 1:00 PM UTC
BusinessCrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology ResearchBy Nasdaq OMXNov 17, 2017, 4:53 PM UTC
BusinessCrown Bioscience Inc. Announcing the 2017 Board of Directors Election ResultsBy Nasdaq OMXNov 9, 2017, 10:21 AM UTC
